Clinical

The data offer novel insights, as comparable data on the drug class is scarce despite 2 JAK inhibitors being approved for use in myelofibrosis and others showing promise.

Complications of note in patients with myeloproliferative neoplasm (MPNs) include ischemic stroke, intracerebral and subarachnoid hemorrhage, microbleeds, posterior reversible encephalopathy syndrome, and dural sinus and cerebral vein thrombosis.

A pair of surveys found that there are knowledge and practice gaps preventing earlier diagnoses of spinal muscular atrophy (SMA) in infants and toddlers.

The advisory committee voted against COVID-19 vaccine booster shots for individuals 16 years and older, but unanimously voted for booster shots for people 65 years and older or who are at high risk of severe COVID-19.

At the 10th anniversary meeting of Patient-Centered Oncology Care®, sessions will cover reducing disparities in cancer care, bringing clinical trials closer to the community, and expanding the scope of what the term "precision medicine" means in cancer care.

This study found that switching from a conventional troponin assay to a high-sensitivity troponin assay resulted in changes to diagnosis patterns and stress testing trends.

Five case reports suggested the anti-BAFF monoclonal antibody was effective at reducing disease activity scores for adults who have neuropsychiatric systemic lupus erythematosus (NPSLE).

Investigators examined medical records spanning 3 decades to look at the effect of poorly differentiated tumor size on outcomes in survival in hepatocellular carcinoma (HCC).

This pivotal phase 3 trial led to the recent approval of lonapegsomatropin for growth hormone deficiency.

Crigler-Najjar Syndrome Type 1 is an ultra-rare disease where treatment relies on a liver transplant or full-day phototherapy sessions.

In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.

David J. Reeves, PharmD, BCOP, of Butler University discusses encouraging results from a recent trial, along with safety questions about the types of patients who weren't studied but are likely to have small cell lung cancer.

Study authors found that knowing a patient’s minimal residual disease status can help pinpoint the right multiple myeloma therapy to improve overall and progression-free survival.

Patients with BRAF-V600 mutated metastatic melanoma have new treatment options to consider, but scientists are still waiting on additional data to help choose which first-line treatments are best for which patients.

Results of a data analysis found once-daily zanubrutinib dosing in patients with mantle cell lymphoma (MCL) is safe and effective.

A case report details the presentation of systemic lupus erythematous in a young, previously healthy individual.

Two posters reviewed impairment after COVID-19 infection and the use of pulmonary rehabilitation to address the symptoms.

A review of cases using MRI with and without contrast agent found perfect or near-perfect agreement in most cases when evaluating patients with short stature for growth hormone deficiency.

Gefapixant successfully improved quality-of-life and reduced cough severity for patients with chronic cough vs placebo, according to 2 posters.

Health care and research need to do a better job of taking into account sex and gender differences that can affect disease, healthy behaviors, and care delivery, according to speakers at the European Respiratory Society International Congress 2021.

Dual bronchodilators have been shown to broadly improve symptoms and quality of life (QOL) in patients with chronic obstructive pulmonary disease (COPD).

During the pandemic, interest in home monitoring grew, and research has shown it can be feasible for patients with interstitial lung disease, according to a presentation at the European Respiratory Society International Congress 2021.

The chief of medical oncology and hematology at Bryn Mawr Hospital and associate principal investigator for Main Line Health's NCI Community Oncology Research Program discusses therapeutic advances along with ongoing challenges in enrolling patients with small cell lung cancer (SCLC) in clinical trials.

Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.

For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.

A review looks at techniques to monitor minimal residual disease (MRD) in patients with multiple myeloma (MM).

Results of the SAFINONMOTOR open-label study found that safinamide was safe and effective in improving pain of patients with Parkinson disease at 6 months.

The murine study, which assessed the combination of foretinib and an anti–PD-1 antibody, found that the regimen enhanced antitumor activity, offering promise in a cancer that has seen less success with immunotherapies than others.

Investigators identified serial liquid biopsy as an effective tool for identifying mutational changes of RAS genes in patients with metastatic colorectal cancer (mCRC) who have undergone antiangiogenic therapy.

Most studies to date that show efficacy with ruxolitinib in this setting have been in adult patients.